Good morning :)
Switch to
Place Order

Lupin Ltd

LUPIN
Health CarePharmaceuticals
MidcapWith a market cap of ₹31,045 cr, stock is ranked 163
Low RiskStock is 1.69x as volatile as Nifty
682.851.07% (-7.40)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
MidcapWith a market cap of ₹31,045 cr, stock is ranked 163
Low RiskStock is 1.69x as volatile as Nifty

Key Metrics

PE RatioPE RatioPB RatioPB RatioDividend YieldDiv. Yield
-20.322.540.59%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
38.164.820.92%

Forecast & RatingsDetailed Forecast 

25%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Lupin Limited is engaged in producing, developing and marketing a range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) across the world.

Brands

Lupin

Pharmaceutical company

Investor PresentationView older 

Aug 4, 2022

PDF
View Older Presentations

Brands

Lupin

Pharmaceutical company

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Financial TrendFinancial statements 

2019202020212022+15.10+15.99+15.30+16.62+0.61-0.27+1.22-1.53
Revenue
Profit
Loss
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent EventsAll events 

Press Release 
Announced OnAug 12, 2022

Lupin Limited has informed the Exchange about press release dated 12-Aug-2022 titled Lupin Receives Approval from U.S. FDA for Meclizine Hydrochloride Tablets USP. | Download

Lupin Limited has informed the Exchange about press release dated 12-Aug-2022 titled Lupin Receives Approval from U.S. FDA for Meclizine Hydrochloride Tablets USP. | Download

Loss of share certificate 
Announced OnAug 10, 2022

Lupin Limited has informed the Exchange about issuance Duplicate Share Certificate. | Download

Lupin Limited has informed the Exchange about issuance Duplicate Share Certificate. | Download

Cash Dividend 
Ex. DateJul 14, 2022

Final • Div/Share: ₹ 4

See all events